New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
06:06 EDTGWPHCNN documentary supports GW's broad approach, says Piper Jaffray
Piper Jaffray believes Sanjay Gupta's CNN special last night entitled "Weed Part 2: Cannabis Madness" further validates GW Pharmaceuticals' broad approach to cannabinoid development. Piper believes GW's manufacturing capabilities and "superior" extraction processes were highlighted on the show. It keeps an Overweight rating on the stock with a $97 price target.
News For GWPH From The Last 14 Days
Check below for free stories on GWPH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
07:51 EDTGWPHGW Pharmaceuticals could trade up 25% on data, says Leerink
Leerink believes shares of GW Pharmaceuticals could trade up 25% should the Epidiolex data in pediatric epilepsy show a seizure reduction materially greater than 44%. The data is expected in the second half of 2014. The firm says shares could trade up 15% higher on a reduction at or close to 40%, or 15% lower if the mean reduction is in the 20%-30% range. Leerink is bullish ahead of the data readout after reviewing the cannabidiol epilepsy literature and previous anti-epileptic drug trials. It has an Outperform rating on shares of GW Pharmaceuticals with a $110 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use